Postmarketing Clinical Study of Ipragliflozin - Long-term Study in Combination With GLP-1 Receptor Agonists in Patients With Type 2 Diabetes Mellitus
Latest Information Update: 17 Sep 2021
Price :
$35 *
At a glance
- Drugs Ipragliflozin (Primary)
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
- Sponsors Astellas Pharma
- 01 Aug 2018 Results published in the Diabetes Therapy.
- 23 Aug 2016 Status changed from active, no longer recruiting to completed.
- 17 Aug 2015 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.